Shares of PepGen, Inc. (PEPG) have gained 22.6% over the past four weeks to close the last trading session at $5.7, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10 indicates a potential upside of 75.4%.The mean estimate comprises six short-term price targets with a standard deviation of $5.83. While the lowest estimate of $3.00 indicates a 47.4% decline from the current pric ...

美股市场表现 - 周三早盘美股涨跌互现 道琼斯指数上涨约100点 涨幅0.23%至47,669.92点 纳斯达克指数下跌0.19%至23,530.68点 标普500指数微涨0.02%至6,842.14点 [1] - 工业股板块领涨 涨幅达0.8% 信息技术股板块表现落后 下跌0.6% [1] 公司业绩与事件 - Chewy Inc 第三季度业绩超预期 调整后每股收益为0.32美元 远超市场一致预期的0.13美元 且处于公司管理层28-33美分的指引区间内 [2] - Chewy Inc 第三季度销售额为31.17亿美元 同比增长8.3% 高于市场一致预期的30.99亿美元 且处于公司管理层30.7-31亿美元指引区间的高端 [2] - Enveric Biosciences Inc 股价大涨102%至11.94美元 原因是其用于治疗精神健康障碍的EVM301系列分子相关专利申请获得了美国专利商标局的授权通知书 [8] - A SPAC III Acquisition Corp 股价飙升336%至45.69美元 [8] - Beasley Broadcast Group Inc 股价大涨135%至9.52美元 [8] - WORK Medical Technology Group LTD 股价暴跌86%至0.7876美元 [8] - Agape ATP Corporation 股价下跌82%至0.2332美元 [8] - Pomdoctor Limited 股价下跌73%至1.4799美元 [8] 大宗商品市场 - 油价下跌0.6%至57.92美元/桶 [4] - 金价下跌0.2%至4,227.60美元/盎司 [4] - 银价上涨0.3%至60.990美元/盎司 [4] - 铜价上涨0.8%至5.3615美元/磅 [4] 全球其他市场 - 欧洲股市涨跌不一 欧元区STOXX 600指数上涨0.1% 西班牙IBEX 35指数上涨0.1% 英国富时100指数上涨0.3% 德国DAX 40指数下跌0.3% 法国CAC 40指数下跌0.4% [5] - 亚洲市场周三多数收跌 日本日经225指数下跌0.10% 香港恒生指数上涨0.42% 中国上证综指下跌0.23% 印度BSE Sensex指数下跌0.32% [6] 宏观经济数据 - 美国第三季度民用工人薪酬成本上涨0.8% 低于上一季度0.9%的涨幅 [7] - 12月第一周抵押贷款申请量环比增长4.8% [9]

POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."All reports on IGC Pharma prep ...

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, ...

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPTO) titled “Spheroids For Cartilage Repair” covering a proprietary fib ...

TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has completed release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules. “PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with o ...

关于内容发布商 - 内容发布商Proactive是一家为全球投资受众提供快速、易获取、信息丰富且可操作的商业与金融新闻内容的机构[2] - 其新闻团队由经验丰富且合格的新闻记者组成，所有内容均独立制作[2] - 公司在全球主要金融和投资中心设有办事处和演播室，包括伦敦、纽约、多伦多、温哥华、悉尼和珀斯[2] 关于内容覆盖范围与专长 - 公司在中小型市值市场领域是专家，同时也向投资社区更新蓝筹股公司、大宗商品及更广泛投资领域的信息[3] - 其提供的内容旨在激发和吸引积极的个人投资者[3] - 团队提供的新闻和独特见解覆盖多个市场领域，包括但不限于生物技术与制药、采矿与自然资源、电池金属、石油与天然气、加密货币以及新兴数字和电动汽车技术[3] 关于内容制作与技术应用 - 公司始终秉持前瞻性思维并积极采用技术[4] - 其人类内容创作者拥有数十年的宝贵专业知识和经验[4] - 团队也会利用技术来协助和增强工作流程[4] - 公司偶尔会使用自动化和软件工具，包括生成式人工智能[5] - 然而，所有发布的内容均由人类编辑和撰写，遵循内容制作和搜索引擎优化的最佳实践[5]

BigBear.ai ( BBAI ) have just made a couple of interesting announcements over the past month. Both announcements point to having a nice foothold in the Middle East. The company first revealed a partnership with Vigilix andI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciati ...

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to support biomarkers to identify patients who benefit from treatment with BriaCell’s regimenMaturing Phase 2 study data continues to support meaningful clinical benefit of the Bria-IMT regimen with outstanding long-term survival No toxicity related discontinuations in Phase 3 PHILADELPHIA and VANCOUVER, British Columbia, D ...

文章核心观点 ProMIS Neurosciences公司宣布其阿尔茨海默病候选药物PMN310的临床前及回顾性临床分析结果在同行评审期刊上发表 研究结果表明 PMN310通过选择性靶向有毒的可溶性Aβ寡聚体 同时避免与单体及斑块结合 有望在提高疗效的同时降低淀粉样蛋白相关成像异常风险 公司计划于2025年底完成PRECISE-AD试验的患者入组 并在2026年第二季度和第四季度分别进行中期分析和公布顶线结果[1][3][11] 药物作用机制与临床前数据 - **靶向特异性**：PMN310在研究中显示出对有毒可溶性Aβ寡聚体的严格特异性 是唯一避免与单体及斑块结合的抗体 而其他测试抗体均不同程度地结合单体或斑块[4][13] - **效力潜力**：在所有测试抗体中 PMN310对单体竞争表现出最高的抵抗力 在体外模型中能保持寡聚体结合活性 而泛Aβ抗体则失去活性 这表明PMN310的更大比例剂量可用于到达相关毒性靶点 从而可能转化为临床获益[6] - **动物模型验证**：在阿尔茨海默病小鼠研究中 这种寡聚体选择性转化为对空间记忆的完全保护 使表现恢复至正常野生型水平[6] 潜在安全性优势 - **降低ARIA风险**：淀粉样蛋白相关成像异常与抗体结合不溶性斑块和血管淀粉样蛋白沉积密切相关 像donanemab aducanumab和lecanemab等抗体显示出显著的斑块结合和相应增加的ARIA发生率 相比之下 PMN310在所有测试浓度下均未检测到斑块结合[5][6] - **临床前安全性证据**：在携带斑块的小鼠中 高剂量长期给药PMN310 剂量为800 mg/kg 持续26周 脑组织显微镜检查未产生微出血[6] 临床试验进展与设计 - **试验状态**：PRECISE-AD是一项针对128名阿尔茨海默病患者的1b期临床试验 计划于2025年底完成患者入组[1][11] - **试验设计**：该研究是一项随机 双盲 安慰剂对照试验 旨在评估静脉注射PMN310在因阿尔茨海默病导致的轻度认知障碍和轻度阿尔茨海默病患者中的安全性 耐受性和药代动力学 测试剂量为5 10 20 mg/kg[11] - **数据读出时间表**：预计在2026年第二季度进行为期6个月的盲态中期分析 并在2026年第四季度获得最终顶线数据[3][11] - **试验意义**：PRECISE-AD将是首个研究仅针对有毒β-淀粉样蛋白寡聚体的单克隆抗体对阿尔茨海默病病理相关生物标志物和临床结局影响的研究 该研究旨在提供95%的置信度来检测ARIA[11] 公司背景与药物定位 - **公司技术平台**：ProMIS Neurosciences是一家临床阶段生物技术公司 专注于发现和开发针对神经退行性疾病中有毒寡聚体的治疗性抗体和疫苗 其专有靶点发现引擎EpiSelect™可预测错误折叠蛋白分子表面的疾病特异性表位[9] - **药物定位**：PMN310是公司治疗阿尔茨海默病的先导候选产品 是一种人源化单克隆抗体 旨在选择性靶向有毒寡聚体 避免斑块 从而可能降低或消除淀粉样蛋白相关成像异常风险 该药物于2025年7月获得美国FDA的快速通道资格认定[10] - **科学验证**：该研究通过并排比较不同Aβ靶向抗体对Aβ物种的结合谱 并与已知临床结果进行比较 为选择性靶向有毒寡聚体以提高疗效和改善安全性的潜力提供了实验和临床支持的进一步证据[3][8]